Chemokine clouding and liver cancer heterogeneity: Does it impact clinical outcomes?
Chemokine receptors
Chemokines
Cytokines
Hepatocellular carcinoma
Heterogeneity
Journal
Seminars in cancer biology
ISSN: 1096-3650
Titre abrégé: Semin Cancer Biol
Pays: England
ID NLM: 9010218
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
22
01
2022
revised:
11
02
2022
accepted:
12
02
2022
pubmed:
22
2
2022
medline:
23
11
2022
entrez:
21
2
2022
Statut:
ppublish
Résumé
Tumor heterogeneity is a predominant feature of hepatocellular carcinoma (HCC) that plays a crucial role in chemoresistance and limits the efficacy of available chemo/immunotherapy regimens. Thus, a better understanding regarding the molecular determinants of tumor heterogeneity will help in developing newer strategies for effective HCC management. Chemokines, a sub-family of cytokines are one of the key molecular determinants of tumor heterogeneity in HCC and are involved in cell survival, growth, migration, and angiogenesis. Herein, we provide a panoramic insight into the role of chemokines in HCC heterogeneity at genetic, epigenetic, metabolic, immune cell composition, and tumor microenvironment levels and its impact on clinical outcomes. Interestingly, our in-silico analysis data showed that expression of chemokine receptors impacts infiltration of various immune cell populations into the liver tumor and leads to heterogeneity. Thus, it is evident that aberrant chemokines clouding impacts HCC tumor heterogeneity and understanding this phenomenon in depth could be harnessed for the development of personalized medicine strategies in future.
Identifiants
pubmed: 35189322
pii: S1044-579X(22)00043-8
doi: 10.1016/j.semcancer.2022.02.015
pii:
doi:
Substances chimiques
Chemokines
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1175-1185Subventions
Organisme : NIGMS NIH HHS
ID : SC1 GM140982
Pays : United States
Informations de copyright
Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors have no conflict of interest to disclose.